ArticleBlood neoplasia2025

Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study.

Trine Trab et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.